Venture funds see golden opportunities in Oresund's life science hub
MVA-members and life science decision-makers should all read the recently published and translated article “Venture funds see golden opportunities in Oresunds’s life science hub“.
Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.
April 3- 6, Loews Meeting Complex at Universal, Orlando, US
Student Jørgen Amdim got to experience life as an orderly on his one-week placement at the Norwegian Radium Hospital.
We are in full preparation for the BioEurope spring in Wienna taking place 25th to 27th March.
New research: A new study may potentially enable scientists to provide cancer immunotherapy that is cheaper, faster and more manageable.
Lund company Bionamic and researchers from Lund University shared first place with another team in a challenge arranged by the US Food and Drug Administration (FDA), and the National Cancer Institute (NCI). Their AI-based computer model achieved 100 percent success in detecting and correcting mislabeled analysis results from tumor biopsies in a complex dataset. The prize is, partly, to publish an article about the work in the science paper Nature Medicine.
The chairman of Medicon Valley Alliance, Søren Bregenholt´s quarterly business column in Copenhagen Post “The Valley of Life: Britain is still key!” has just been published.
The laboratories at Oslo Cancer Cluster Incubator are expanding to meet increasing demand from members.
In an interview with LIFe-time.se, Medicon Valley Alliance CEO, Petter Hartman, is commenting on the new proposals for strengthening life science in Region Skåne. The region needs to be even better at attracting clinical trials, but what else is needed?
Dr. Jon Amund Kyte at Oslo University Hospital (OUH) and Oslo Cancer Cluster share the common goal of bringing more clinical trials to Norway.
Targovax, one of the members of Oslo Cancer Cluster, has begun an expansion patient group in the clinical trial of a drug to treat skin cancer.
Spago Nanomedical AB (publ) will present preclinical data for SpagoPix at the conference European Congress of Radiology (ECR) this week
An estimated 700,000 people die each year worldwide from bacterial infections. New antibiotics, rapid diagnostics, vaccines and other products are urgently needed to treat bacteria that are increasingly resistant to existing antibiotics. This is the challenge adressed by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which is now expanding its Global Accelerator Network to include among others BII.